EP3272339A1 - Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol - Google Patents

Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol Download PDF

Info

Publication number
EP3272339A1
EP3272339A1 EP17172870.2A EP17172870A EP3272339A1 EP 3272339 A1 EP3272339 A1 EP 3272339A1 EP 17172870 A EP17172870 A EP 17172870A EP 3272339 A1 EP3272339 A1 EP 3272339A1
Authority
EP
European Patent Office
Prior art keywords
desmethyltramadol
hours
tramadol
released
desmethyltramadol released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17172870.2A
Other languages
English (en)
French (fr)
Inventor
John A. Zebala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntrix Biosystems Inc
Original Assignee
Syntrix Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntrix Biosystems Inc filed Critical Syntrix Biosystems Inc
Publication of EP3272339A1 publication Critical patent/EP3272339A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
EP17172870.2A 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol Withdrawn EP3272339A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506092P 2011-07-09 2011-07-09
EP12810860.2A EP2729134B1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP12810860.2A Division EP2729134B1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol
EP12810860.2A Division-Into EP2729134B1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol

Publications (1)

Publication Number Publication Date
EP3272339A1 true EP3272339A1 (de) 2018-01-24

Family

ID=47438792

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12810860.2A Active EP2729134B1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol
EP17172870.2A Withdrawn EP3272339A1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12810860.2A Active EP2729134B1 (de) 2011-07-09 2012-07-09 Zusammensetzungen und verfahren zur überwindung einer resistenz gegen tramadol

Country Status (14)

Country Link
US (6) US10702485B2 (de)
EP (2) EP2729134B1 (de)
CY (1) CY1119597T1 (de)
DK (1) DK2729134T3 (de)
ES (1) ES2650368T3 (de)
HR (1) HRP20171743T1 (de)
HU (1) HUE037341T2 (de)
LT (1) LT2729134T (de)
NO (1) NO2833973T3 (de)
PL (1) PL2729134T3 (de)
PT (1) PT2729134T (de)
RS (1) RS56570B1 (de)
SI (1) SI2729134T1 (de)
WO (1) WO2013009666A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
DE102013009114A1 (de) * 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
EP2922348A1 (de) * 2014-03-21 2015-09-23 Alcatel Lucent Netzwerkkonfiguration
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
WO2016086194A1 (en) 2014-11-26 2016-06-02 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
CA3024081A1 (en) * 2015-05-11 2016-11-17 Demerx, Inc. Methods for treatment of opioid dependency and withdrawal using noribogaine
US11000488B2 (en) * 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CN113861048A (zh) * 2020-06-30 2021-12-31 南京诺瑞特医药科技有限公司 去甲曲马多的盐及其用途

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US5336691A (en) 1991-09-06 1994-08-09 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5427799A (en) 1992-03-25 1995-06-27 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591452A (en) 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5728885A (en) 1996-01-19 1998-03-17 Gruenenthal Gmbh Method of preparing the enantiomers of O-dimethyltramadol
DE19712398A1 (de) * 1997-03-25 1998-10-01 Gruenenthal Gmbh Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6143327A (en) 1998-10-30 2000-11-07 Pharma Pass Llc Delayed release coated tablet of bupropion hydrochloride
WO2001024783A2 (de) * 1999-10-05 2001-04-12 Grünenthal GmbH Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6297286B1 (en) 1999-11-09 2001-10-02 Darwin Discovery, Ltd. Therapeutic use and formulation
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
WO2002066025A2 (de) * 2001-02-21 2002-08-29 Grünenthal GmbH Wirkstoffkombination aus dem racemat des tramadols und dem (+)-o-desmethyltramadol
US6723343B2 (en) 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
US7611730B2 (en) 2001-02-21 2009-11-03 Grunenthal Gmbh Tramadol-based medicament
US7906141B2 (en) 1999-08-31 2011-03-15 Gruenenthal Gmbh Sustained-release, oral pharmaceutical forms of formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5023083A (en) * 1987-09-23 1991-06-11 William Drell Azarbine composition
MX9205106A (es) 1991-09-06 1993-05-01 Johnson & Johnson Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
EP1003476B1 (de) * 1997-08-11 2004-12-22 ALZA Corporation Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
ES2141688B1 (es) 1998-11-06 2001-02-01 Vita Invest Sa Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
CZ2002524A3 (cs) 1999-08-20 2002-11-13 Ortho-Mcneil Pharmaceutical, Inc. Kompozice obsahující tramadol a antikonvulziva
US6339105B1 (en) 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
US6326404B1 (en) 2000-02-21 2001-12-04 Gruenenthal Gmbh Use of O-desmethyl-N-mono-desmethyl-tramadol
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US20030077222A1 (en) 2001-05-07 2003-04-24 Mcgill University Individualization of therapy with analgesics
US20060147527A1 (en) 2002-12-13 2006-07-06 Cilag Ag Controlled release preparations comprising tramadol and topiramate
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2005000285A2 (en) 2003-06-13 2005-01-06 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
DE10332486A1 (de) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
WO2007087452A2 (en) 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
TWI449542B (zh) 2006-03-30 2014-08-21 Nippon Zoki Pharmaceutical Co 固形醫藥製劑
CA2661818A1 (en) 2006-05-03 2007-11-15 Kowa Pharmaceuticals America, Inc. Acute pain medications based on fast acting diclofenac-opioid combinations
JP5453280B2 (ja) 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009117130A2 (en) 2008-03-21 2009-09-24 Mylan Pharmaceuticals, Inc. Extended release forumulation containing a wax
KR20110036858A (ko) 2008-10-27 2011-04-11 알자 코퍼레이션 지속 방출형 경구용 아세트아미노펜/트라마돌 제형
CA2750144C (en) 2008-12-31 2016-10-25 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4116241A (en) 1976-02-02 1978-09-26 Alza Corporation Osmotic system with laminated wall comprising structurally different semipermeable lamina
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US5336691A (en) 1991-09-06 1994-08-09 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5427799A (en) 1992-03-25 1995-06-27 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5591452A (en) 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US6254887B1 (en) 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US7074430B2 (en) 1993-05-10 2006-07-11 Euro-Celtique S.A. Controlled release tramadol tramadol formulation
US5728885A (en) 1996-01-19 1998-03-17 Gruenenthal Gmbh Method of preparing the enantiomers of O-dimethyltramadol
DE19712398A1 (de) * 1997-03-25 1998-10-01 Gruenenthal Gmbh Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6143327A (en) 1998-10-30 2000-11-07 Pharma Pass Llc Delayed release coated tablet of bupropion hydrochloride
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
US7906141B2 (en) 1999-08-31 2011-03-15 Gruenenthal Gmbh Sustained-release, oral pharmaceutical forms of formulation
US6723343B2 (en) 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
WO2001024783A2 (de) * 1999-10-05 2001-04-12 Grünenthal GmbH Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
US6660774B2 (en) 1999-10-05 2003-12-09 Gruenethal Gmbh Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol
US6297286B1 (en) 1999-11-09 2001-10-02 Darwin Discovery, Ltd. Therapeutic use and formulation
US7611730B2 (en) 2001-02-21 2009-11-03 Grunenthal Gmbh Tramadol-based medicament
WO2002066025A2 (de) * 2001-02-21 2002-08-29 Grünenthal GmbH Wirkstoffkombination aus dem racemat des tramadols und dem (+)-o-desmethyltramadol
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Sustained-Release Drug Delivery Systems", pages: 1660 - 1675
COLLART ET AL.: "Partial inhibition of tramadol antinociceptive effect by naloxone in man", BR. J. CLIN. PHARMACOL., vol. 35, 1993, pages 73P
DESMEULES ET AL.: "Contribution of monoaminergic modulation to the analgesic effect of tramadol", BR. J. CLIN. PHARMACAL., vol. 41, no. 1, 1996, pages 7 - 12
GANIDO ET AL.: "Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-0-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats", J. PHARMACOL. EXP. TITER., vol. 295, no. 1, 2000, pages 352 - 359
HIGUCHI T.: "Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices", JPHARM SCI., vol. 52, 1963, pages 1145 - 1149
KAYSER ET AL.: "Effects of the analgesic agent tramadol in normal and arthritic rats: comparison with the effects of different opioids, including tolerance and cross-tolerance to morphine", EUR. J. PHARMACAL., vol. 195, no. 1, 1991, pages 37 - 45
KAYSER ET AL.: "Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat", EUR. J. PHARMACOL., vol. 224, no. 1, 1992, pages 83 - 88
KIRCHHEINER ET AL.: "Effects of die CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol", J. CLIN. PSYCHOPHARMACOL., vol. 28, no. 1, 2008, pages 78 - 83
KIRCHHEINER ET AL.: "Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol", J. CLIN. PSYCHOPHAMIACOI, vol. 28, no. 1, 2008, pages 78 - 83
KIRCHHEINER ET AL.: "Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol", J. CLIN. PSYCHOPHARMACOL, vol. 28, no. 1, 2008, pages 78 - 83
KUKANICH; PAPICH: "Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs", J. VET. PHARMACOL. THER., vol. 27, no. 4, 2004, pages 239 - 246
LAI J ET AL: "TRAMADOL, M1 METABOLITE AND ENANTIOMER AFFINITIES FOR CLONED HUMAN OPIOID RECEPTORS EXPRESSED IN TRANSFECTED HN9.10 NEUROBLASTOMA CELLS", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 316, no. 2/03, 1 January 1996 (1996-01-01), pages 369 - 372, XP002070463, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(96)00770-4 *
POTSCHKA ET AL.: "Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its Ml metabolite in the rat kindling model of epilepsy", BR. J. PHARMACOL., vol. 131, no. 2, 2000, pages 203 - 212
POULSEN ET AL.: "The hypoalgesic effect of tramadol in relation to CYP2D6", CLIN. PHARMACOL. THER., vol. 60, no. 6, 1996, pages 636 - 644
RAFFA ET AL.: "Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol", J. PHARMACOL. EXP. THER., vol. 267, no. 1, 1993, pages 331 - 340
RAFFA ET AL.: "Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic", J. PHARMACAL. EXP. THER., vol. 260, no. 1, 1992, pages 275 - 285
RAFFA ET AL.: "Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic", J. PHARMACOL. EXP. THER., vol. 260, no. 1, 1992, pages 275 - 285
RAFFA ET AL.: "Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic", J. PHARMACOL. EXP. TILER., vol. 260, no. 1, 1992, pages 275 - 285
RAFFA: "Basic pharmacology relevant to drug abuse assessment: tramadol as example", J. CLIN. PHARM. TLXER., vol. 33, no. 2, 2008, pages 101 - 108
REMINGTON: "The Science and Practice of Pharmacy", article "Solutions, Emulsions, Suspensions and Extracts", pages: 1503 - 1505
ROJAS-CORRALES ET AL.: "Tramadol Induces Antidepressant-Type Effects In Mice", LIFE SCIENCES, vol. 63, no. 12, 1998
SEVCIK J ET AL: "EFFECTS OF THE CENTRAL ANALGESIC TRAMADOL AND ITS MAIN METABOLITE, O-DESMETHYLTRAMADOL, ON RAT LOCUS COERULEUS NEURONES", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS; GB, vol. 110, 1 January 1993 (1993-01-01), pages 169 - 176, XP002070462, ISSN: 0007-1188 *
STAMER ET AL.: "Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes", CLIN. PHARMACOL. THER., vol. 82, no. 1, 2007, pages 41 - 47
STAMER ET AL.: "Impact of CYP2D6 genotype on postoperative tramadol analgesia", PAIN, vol. 105, no. 1-2, 2003, pages 231 - 238
UNITED STATES PHARMACOPEIA, vol. 1, pages 813
WANG ET AL.: "Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population", EUR. J. CLIN. PHARMACOL, vol. 62, no. 11, 2006, pages 927 - 931

Also Published As

Publication number Publication date
RS56570B1 (sr) 2018-02-28
EP2729134A1 (de) 2014-05-14
NO2833973T3 (de) 2018-02-10
US20170319511A1 (en) 2017-11-09
CY1119597T1 (el) 2018-04-04
US9808432B2 (en) 2017-11-07
US10702485B2 (en) 2020-07-07
PT2729134T (pt) 2017-11-24
EP2729134B1 (de) 2017-08-23
LT2729134T (lt) 2017-10-10
US20170319510A1 (en) 2017-11-09
ES2650368T3 (es) 2018-01-18
WO2013009666A1 (en) 2013-01-17
EP2729134A4 (de) 2015-03-04
US9717700B2 (en) 2017-08-01
US20160220514A1 (en) 2016-08-04
PL2729134T3 (pl) 2018-01-31
US20160074341A1 (en) 2016-03-17
US20130011444A1 (en) 2013-01-10
HRP20171743T1 (hr) 2017-12-29
SI2729134T1 (sl) 2017-12-29
US20150342905A1 (en) 2015-12-03
DK2729134T3 (en) 2017-10-09
US9717701B2 (en) 2017-08-01
HUE037341T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
US9717700B2 (en) Methods for overcoming resistance to tramadol
EP2603205B1 (de) Verwendung von bindungsmitteln zur herstellung von lagerungsstabilen formulierungen
AU2013344281B2 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EP2568967B1 (de) Pharmazeutische zusammensetzungen mit hydromorphon und naloxon
EP2251012A1 (de) Tablette mit verbesserten elutionseigenschaften

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170623

AC Divisional application: reference to earlier application

Ref document number: 2729134

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/22 20060101AFI20200624BHEP

Ipc: A61K 9/28 20060101ALI20200624BHEP

Ipc: A61K 31/135 20060101ALI20200624BHEP

INTG Intention to grant announced

Effective date: 20200724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201204